European Medicines Agency recommends granting a conditional marketing authorisation for brentuximab vedotin
Brentuximab vedotin is intended for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma and systemic anaplastic large cell lymphoma
On 19 July 2012, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product brentuximab vedotin (Adcetris), 50 mg, powder for concentrate for solution for infusion, intended for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma in two conditions: (1) following autologous stem cell transplant (ASCT) or (2) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, as well as for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Brentuximab vedotin was designated as an orphan medicinal product on 15 January 2009. The applicant for this medicinal product is Takeda Global Research and Development Centre (Europe) Ltd. They may request a re-examination of any CHMP opinion, provided they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.
How does brentuximab vedotin work?
The active substance of Adcetris is brentuximab vedotin, a monoclonal antibody (L01XC12) drug conjugate that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells. The antitumour activity of brentuximab vedotin has been established in the Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma study populations, as well as in the relapsed or refractory Hodgkin lymphoma patients ineligible for ASCT/multidrug chemotherapy. The different clinical endpoints demonstrated clinical benefit in terms of disease control, resolution of B-symptoms and in terms of enabling further potentially curative treatment options.
The most common side effects are peripheral sensory neuropathy, fatigue, nausea, diarrhoea, neutropenia, vomiting, pyrexia, and upper respiratory tract infection.
A pharmacovigilance plan for brentuximab will be implemented as part of the marketing authorisation.
The approved indication is: "Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma:
- following autologous stem cell transplant (ASCT) or
- following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).”
It is proposed that brentuximab vedotin be prescribed by physicians experienced in the use of anti-cancer agents.
Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for brentuximab vedotin and therefore recommends the granting of the marketing authorisation. The marketing authorisation is conditional.
Thank you for rating!
You have already rated this page, you can only rate it once!